Anzeige
Erschienen in:
01.11.2012 | Brief report
Diabetic nephropathy is associated with prostate-specific antigen levels in type 2 diabetes mellitus
Erschienen in: Cancer Causes & Control | Ausgabe 11/2012
Einloggen, um Zugang zu erhaltenAbstract
Purpose
Type 2 diabetes is associated with reduced risk of prostate cancer and low prostate-specific antigen levels for uncertain reasons. Recently, two studies demonstrated the time course of diabetes with prostate-specific antigen levels, which would be explained by the chronic renal complication. Therefore, we conducted a retrospective study to determine whether diabetic nephropathy is associated with prostate-specific antigen levels.
Methods and results
Eligible patients were men aged ≥40 years, with type 2 diabetes and a recorded prostate-specific antigen level. Patients with a prior history of prostate cancer or prostatectomy or prostate-specific antigen level ≥10 ng/mL and patients with end-organ damage were excluded. Of the 247 patients included in the adjusted analysis, 51 (20.8 %) were diagnosed with diabetic nephropathy. A significant association of diabetic nephropathy with log-transformed prostate-specific antigen level was detected (Spearman’s correlation coefficient −0.201, p = 0.003; adjusted for all other correlated variables) and fit into a linear regression model (B-coefficient −0.331, p = 0.003). Comparing diabetic nephropathy group with non-diabetic nephropathy group, the difference in log-transformed prostate-specific antigen levels was also significant (p = 0.002).
Conclusion
The results indicated that patients with diabetic nephropathy have low prostate-specific antigen levels, suggesting fewer prostate cancers being detected or fewer incidences among this group.